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Brown AlgaeAbstract Osteogenesis imperfecta as the name suggests, is a bone disorder characterised by imper-
fect bone mineralisation and development. The key defect lies in the osteoblast–osteoid cycle, lead-
ing to insufﬁcient calciﬁcation and consequently weak bones. Osteogenesis imperfecta patients are
prone to fractures. Till date, numerous growth hormone/synthetic analogues have been used ther-
apeutically in osteogenesis imperfecta patients and they do provide temporary relief, but not with-
out numerous unwanted side effects. The intervention offered by such treatments is mainly at the
symptomatic level, with temporary pain relief and some degree of mineralisation of available oste-
oids; but the root cause of the disease remains unattended. Such treatment modalities fail to pro-
mote mesenchymal stem cell osteogenic differentiation and tackle the fundamental deﬁciency of
osteoids. This paper suggests a unique and hitherto unimplemented approach for treatment of
osteogenesis imperfecta at the cellular level through application of a natural source, ‘Brown algae
isolated phlorotannins’, which promote mesenchymal stem cell differentiation by increasing alka-
line phosphatase activity, calciﬁc mineralisation and total protein and collagen synthesis. This nat-
ural extract, when integrated directly with mesenchymal stem cells, will boost cellular differentiation
into healthy bone-forming cells. The modality will strengthen the bone intrinsically and without the
adverse reactions of routine pharmacotherapeutic agents.
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Figure 1 Schematic ﬂowchart of mesenchymal stem cells (MSCs)
differentiation into osteoblasts through natural brown algae
extract stimulation.
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Stem cells are biological cells found in all multicellular organ-
isms, which can differentiate and self-renew to produce more
cells of their like. Stem cells found in bone marrow are called
mesenchymal stem cells (MSCs). The presence of MSCs in
bone marrow was ﬁrst suggested by Friedenstein et al. in
1976 [1]. Recent studies have demonstrated the clinical applica-
tion of MSCs in improving haematopoietic engraftment, pre-
venting graft versus host disease and correcting disease
conditions of bones including fracture nonunion, metabolic
bone disorders and genetic disorders such as osteogenesis
imperfecta (OI) [2]. It has been observed that human MSCs
proliferate most rapidly in culture and retain their multi-po-
tency even at relatively low densities [3].
Current research has established the role of natural factors
such as transforming growth factor-b1 (TGF-b1), interleukin-
1b (IL-1b) and tumour necrosis factor-a (TNF-a) in inducing
differentiation of human tissue-derived MSCs, activating bio-
logical processes such as cell survival, cell migration, cell adhe-
sion, chemokine production, induction of angiogenesis and
modulation of immune response, MSC proliferation, migra-
tion and adhesion to extracellular matrix components such
as collagen and laminin as well as activation of intracellular
anti-inﬂammatory survival pathways. These effects are medi-
ated via a speciﬁc chemotactic effect on human MSCs through
complex receptor and signalling pathways [4].
With reference to numerous ongoing clinical trials using
MSCs, special attention ought to be directed towards their
potential role in OI treatment. This genetic disorder results
from mutations in the collagen I gene, causing abnormalities
in bone structure and strength. Over 150 mutations are
responsible for the OI outcome, involving collagen precursor
genes such as COL1A1 and COL1A2. As collagen is the ma-
jor protein responsible for building extracellular matrix and
bone strength, patients with OI suffer from defective colla-
gen-induced inadequate bony matrix, weak bones, frequent
and numerous fractures, progressive deformities of limbs
and spine, retarded growth and short stature. Therefore,
the disease is commonly known as ‘brittle bone disease’.
Hypothesis
Administration of phlorotannins isolated from brown algae
into MSC culture will result in the formation of an integrated
natural compound that will enhance cellular differentiation
into osteogenic precursors in vitro. These ‘natural extract’-trea-
ted MSCs, when administered in-vivo (in the bone marrow of
an OI patient), will resort to good-quality matrix mineralisa-
tion and osteogenic lay-down, thereby strengthening the bone
intrinsically.
Evaluation of hypothesis
Phlorotannins found in brown algae promote osteogenesis by
increasing alkaline phosphatase activity, stimulating total pro-
tein synthesis, calciﬁc mineralisation and collagen synthesis.
Further, recent evidence suggests the potential of MSCs in
treating bone conditions. Phlorotannins, if integrated ‘directly’with MSCs, will improve bone strength through ameliorating
the structural integrity of collagen proteins and other matrix
proteins, thereby promoting formation of new, healthy bone
cells. This ‘integrated therapeutic approach’ will serve to col-
late and combine the osteogenic potential of two resources
simultaneously – MSCs and phlorotannins – to aid in better-
quality bone matrix development. This modality appears to
be an effective and logical intervention for OI at the cellular
level.
Description of the study
The experimental design (Figs. 1 and 2) entails serial dilution
of brown algae pigment (phlorotannin) extracts for the deter-
mination of an ‘ideal phlorotannin dose’ for achieving optimal
bone mineralisation in OI patients. As phlorotannins are nat-
ural extracts of brown algae, their direct transplantation into
the bone marrow of an OI patient will carry minimalistic side
effects characteristic of innovative nature-based therapeutic
approaches.
Our suggested strategy entails the following procedures:
Drug Neupogen (ﬁlgrastim, granulocyte colony stimulating
factor) will be administered in a human OI disease model
in order to facilitate stem cell migration from the bone mar-
row to blood. MSCs will be collected from the peripheral
blood of OI patients followed by MSC culture in Eagle’s
medium and phosphate buffer wash. The debris will be sep-
arated by ultra-centrifugation. MSCs will be isolated by the
‘adherence to plastic method’ [5]. This will be followed by
segregation of MSCs in a Petri dish and letting them ‘rest’
Figure 2 Illustrative representation of the events that occur in the mesenchymal stem cell (MSC) osteogenic proliferation through
natural brown algae extract stimulation.
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till a large cluster of cells is formed. Serial dilutions of
brown algae-derived phlorotannins will be prepared. Groups
of MSCs will be isolated in different test tubes and treated
with sequential dilutions of the natural extract. Each of the
new MSC colonies will be allowed to multiply for 21 days
with weekly medium change. The Alizarin staining method
will be used to detect mineralised matrices [6], where a
darkened colour will indicate better matrix mineralisation
and osteogenesis. Qualitative rating of bone structure will
be done microscopically for each MSC colony in order to
spot the best ‘bony lay-down’. An ‘ideal dose’ of natural ex-
tract in terms of ‘extract to MSCs to bone differentiation’
will be done through graphic cell mapping and statistical
correlation.
Suggested precautions to rule out confounding factors
Diseases such as inﬂammatory bowel disease, diabetes, mul-
tiple sclerosis and chronic toxicity increase the level of
inﬂammatory cytokines [7,8]. These cytokines increase the
rate of ‘stem cell niche ageing’, thereby resulting in dimin-
ished tissue repair and hampered therapeutic progress. Care
will be taken for prior identiﬁcation of such inﬂammatory
conditions.
During in-vitro studies, chances of contamination in cell lin-
ing are possible. In order to avoid this, work will be done in
labs equipped with HEPA ﬁlters and standardised aseptic
conditions.
During cellular isolation, cell rupture might occur. Cell iso-
lation will be performed carefully because damaged cells might
affect the quantity as well as quality of bone matrix formation
or bafﬂe results.
It is essential to avoid chemical contamination during cell
culture, which might cause mutations in cell linings.
Final appraisal of the procedure through advanced bone
biomarkers
Objective assessment of therapeutic efﬁcacy:A member of the immunoglobulin superfamily, cyclooxy-
genase-2 (COX-2) (CD200) [9], expression pattern variations
from high to medium and low in bone marrow-derived MSC
cell lines will help in objective assessment of the efﬁcacy of
our technique.
Risk reduction and early intervention:
Cancer stem cells are thought to be responsible for tumour
initiation, dissemination and treatment failure [6]. Therefore,
we suggest identiﬁcation of groups of patients susceptible to
uninhibited stem cell growth (tumerogenesis/carcinogenesis).
Biomarkers such as bone cancer stem cell markers may be
capable of predicting medical progression, risk stratiﬁcation
and therapeutic beneﬁt.
Suggested limitations of the hypothesis
The biomedical mechanism of exactly ‘how’ the phlorotannin-
generated matrix protein affects proliferation of osteoblasts
needs to be clariﬁed. Till these phlorotannin-mediated complex
receptor and signalling pathways and matrix metalloproteinase
expressions are completely decoded, harnessing the full poten-
tial of this novel cell-regulated biochemical intervention will be
impossible.
Furthermore, apart from bone biomarkers, no other reli-
able technique is presently available for objective assessment
of the efﬁcacy of our procedure or predicting medical progres-
sion, risk stratiﬁcation and therapeutic beneﬁt.
The isolation and culture of MSCs and their incorporation
with phlorotannin pigment extracts, which forms the funda-
mental basis of the suggested approach, is a tedious procedure
and prone to frequent confounding factors resulting from cell
rupture, cell line chemical contamination, daughter cell lineage
mutations and faulty qualitative assessment of bone matrix
mineralisation.
Discussion
In OI patients, MSCs become mutated and are incapable
of differentiating into osteoblasts. With lower osteoblast
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88 T.F. Ali, T. Hasanconcentration, it is difﬁcult to achieve appropriate bone den-
sity and consequently, the bone remains under-mineralised
and brittle. Our hypothesis presents a novel cell-based ther-
apy, by stimulating MSCs’ osteogenic proliferation through
the medium of brown algae extracts (phlorotannins). Ecklo-
nia cava (EC) is a member of Laminariaceae family, an edi-
ble marine brown alga with various bioactivities [10].
Role of phlorotanin in osteogenesis
It has been suggested that phlorotannins isolated from brown
algae stimulate the synthesis of collagen or some related pro-
tein and this matrix protein interacts with cell surface adhesion
receptors to stimulate the proliferation of osteoblasts [11]. The
mechanism of how such a protein affects the proliferation of
osteoblasts yet remains to be clariﬁed by further biomedical re-
search. Ryu et al. [10], in their study on differentiation of hu-
man osteosarcoma cells by isolated phlorotannins, have found
that phlorotannin derivatives such as dieckol, dihydroxyphen-
oxy, trihydroxyphenoxy and trihydroxydibenzo dioxins pro-
mote osteosarcoma differentiation by increasing alkaline
phosphatase activity, mineralisation, total protein and colla-
gen synthesis in human osteosarcoma cells. Furthermore, these
phlorotannin derivatives promote cell differentiation, inhibit
messenger RNA (mRNA) gene and protein levels of matrix,
attenuate matrix metalloproteinase expressions and inhibit
the inﬂammatory response in chronic articular diseases.
This prompts a further reﬂection on the promising role of
brown algae phlorotannins in bone marrow MSC prolifera-
tion and differentiation to possibly cure OI patients through
cell-regulated biochemical intervention. On the basis of the
aforementioned assumption, we suggest that if such a vital
bony precursor as ‘phlorotannin’ is incorporated ‘directly’
into MSCs, it will enhance osteogenic proliferation, collagen
synthesis and boney lay-down. Increased availability of oste-
oblasts and osteoids will facilitate auxiliary mineralisation
for better quality bone formation. The degree of bony differ-
entiation can be regulated in vitro through serial concentra-
tions of natural extract. The ‘ideal concentration’ for
achieving best bone mineralisation can be predetermined.
These ‘ideal dose’ treated MSCs can subsequently be intro-
duced in vivo through direct transplantation into the bone
marrow of an OI patient. The ‘modiﬁed’ MSCs will be capa-
ble of much faster proliferation into osteogenic precursors;
hence, more osteoblasts and osteoids will be available for
calciﬁcation/mineralisation and better quality bone will be
formed. In this way, OI will be treated at the cellular level
and the bone will be strengthened from ‘within’. Moreover,
as brown algae-isolated phlorotannins comprise of simple
primeval biological agents, there might be minimal or no
side effects.
Conclusion
MSCs incorporated with phlorotannins will provide a un-
ique alternative therapy to cure a dilapidating medical con-
dition such as OI. It will also stimulate the interest of
research personnel towards the un-harvested therapeutic po-
tential of the gifts of nature in the form of complementary/
nature therapy.verview Box
First question: What do we already know about the
subject?e of adult stem cells, such as mesenchymal stem cells
SCs) derived from bone marrow, is an innovative
atment for many disease conditions of bones,
luding fracture nonunion and metabolic bone disor-
s. Phlorotannins isolated from brown algae stimu-
e the synthesis of collagen or some related protein
d this matrix protein interacts with cell surface adhe-
n receptors to stimulate collagen integrity and pro-
ration of osteoblasts.
cond question: What does your proposed theory add to
current knowledge available and what beneﬁts does it
ve?
r theory proposes an ‘integrated therapeutic ap-
ach’ to collate and combine the osteogenic potential
these two resources: MSCs and phlorotannins. The
wn algae pigment extract’s direct incorporation
o MSCs will result in better quality bone matrix for-
tion and intervention for osteogenesis imperfecta
I) at the cellular level.
r theory seeks to beneﬁt both the clinical orthopa-
cians and the medical researchers. Physicians will
offered a promising ‘natural source’- based therapy
OI with fewer side effects for patients. Researchers
l be offered a dynamic platform for further explora-
n into the potential of cell biologics. Our hypothesis
l address the problem of OI based on simple phar-
cokinetic parameters without any serious side ef-
ts. This hypothesis hopes to provide a platform for
icious treatment of OI with the help of nature.
ird question: Among numerous available studies, what
cial further study is proposed for testing the idea?
e biomedical mechanism of exactly ‘how’ the
lorotannin-generated matrix protein affects prolifer-
on of osteoblasts needs to be clariﬁed. Identiﬁcation
accurate matrix metalloprotease protein expressions
uld lead to a reliable and effective natural therapy
hout the side effects of allopathic medicine. Fur-
rmore, employing advanced bone biomarkers such
bone cancer stem cell markers may help in the objec-
e assessment of the efﬁcacy of our technique and
dicting medical progression, risk stratiﬁcation and
rapeutic beneﬁt.References
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